MIM
NMRA icon

MetLife Investment Management’s Neumora Therapeutics NMRA Stock Holding History

MetLife Investment Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,243
Closed -$554K – 2811
2024
Q4 		$554K Buy
52,243
+2,933
+6% +$35.2K ﹤0.01% 1744
2024
Q3 		$651K Hold
49,310
– – ﹤0.01% 1637
2024
Q2 		$485K Buy
49,310
+40,823
+481% +$422K ﹤0.01% 1729
2024
Q1 		$117K Hold
8,487
– – ﹤0.01% 2465
2023
Q4 		$145K Buy
+8,487
New +$104K ﹤0.01% 2414

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

MetLife Investment Management's NMRA Position: Q1 2025 in Review

MetLife Investment Management sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 52,243 shares — an estimated $554K sold.

MetLife Investment Management first reported a position in NMRA in Q4 2023 and held it in 5 quarters. The position peaked at $651K in Q3 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • MetLife Investment Management reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • MetLife Investment Management sold 52,243 Neumora Therapeutics shares in Q1 2025, an estimated $554K.
  • MetLife Investment Management first reported a position in Neumora Therapeutics in Q4 2023 and held it in 5 quarters.
  • MetLife Investment Management's Neumora Therapeutics position peaked at $651K in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.